Friday, 27 Mar 2020

You are here

Random Drug Levels and Anti-Drug Antibodies Predict Rheumatoid Outcomes

Researchers from Manchester, UK have reported the results of their BRAGGSS study showing that certolizumab (CZP) random drug levels and anti-drug antibody (ADAbs) levels can predict optimal outcomes in CZP treated rheumatoid arthritis patients. 

Monoclonal antibody based therapies are known to result in ADAbs that may impair responses or contribute to adverse events.  Interestingly, assays for both ADAbs and drug trough levels have become increasingly popular in inflammatory bowel disease patients, where it is thought to be predictive.  Amongst rheumatologists their use has not gained traction, with most rheumatologists claiming that their management success has been high without such expensive and not readily obtained assays.

BRAGGSS (Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate) is a CZP prospective cohort study involving 60 centers in the UK.

Their prospective cross-sectional analysis of 115 RA patients treated with CZP, blood samples involved the collections at 3, 6 and 12 months. Randomly obtained, serum samples were assayed for CZP drug levels and ADAbs by ELISA and radioimmunoassay.

ADAbs were detected in 37% at 12 months and were significantly associated with lower drug levels over 12 months.

Drug level was associated with 12 months EULAR response (p=0.042). In the multivariate model, ADAb level and adherence to drug were significantly associated with drug concentrations.

This study demonstrates that practical assessments with random drug levels may be clinically useful. In their study, higher CZP drug levels were associated with better clinical responses at 12 months. Moreover, the development of ADAbs were predictably correlated with low drug levels and lesser clinical responses.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Start with Anti-TNF in RA? Not So Fast

The suggestion to hit rheumatoid arthritis (RA) early and hard with biologic therapies itself took a hit in a new study.

Use of first-line etanercept (Enbrel) plus methotrexate in very early RA was not associated with a substantially higher rate of remission compared with a strategy of treat-to-target methotrexate monotherapy, a randomized open-label trial found.

Best of 2019 - The Shame Behind Adalimumab Biosimilars

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

Psoriasis Risk Increased with TNF Inhibitors in Juveniles

Children with inflammatory diseases who were treated with tumor necrosis factor (TNF) inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, a single-center retrospective study found.

The Shame Behind Adalimumab Biosimilars

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

Pain Persists Despite TNF Inhibitor Use

Control of pain in patients with rheumatoid arthritis (RA) often focuses on control of inflammation as a means to better control pain. However, a new claims data study shows that while anti-tumor necrosis factor inhibitor (TNFi) may lower the use of opioids, the reduction is nominal, suggesting that a substantial amount of pain is not adequately addressed by TNFi - a potent anti-inflammatory approach.